TherapeuticsMD reported their FY23 results yesterday and the last paragraph caught my attention. I am not sure if Mayne Pharma could be in negotiations here or what they might be seeking if they were. Mayne has expressed a desire to list in the US at some point so perhaps a merger with an automatic listing in the NASDAQ. This is pure speculation on my part. THMD has a market capitalisation of US$25MFull Year 2023 Financial Results
Net Income (Loss) from Continuing Operations
- Net loss from continuing operations was $(7.7) million, or $(0.74) per basic and diluted common share, compared to net income from continuing operations of $1.1 million, or $0.12 per basic and $0.11 per diluted common share, for 2022.
License and Service Revenues from Continuing Operations
- Gross license royalties totaled approximately $4.5 million under the Mayne License Agreement for the full year ending December 31, 2023. Included in this amount are $3.0 million of gross minimum royalty payments paid under the Mayne License Agreement. The Company recognizes license revenue only on amounts in excess of the gross minimum royalty amounts earned under the Mayne License Agreement. Our net license royalty income is allocated and reported in revenue, net and other income based on the proportion of the sales from each of our licensed products. Based on sales of our licensed products, the Company recognized $1.3 million in revenue, net and approximately $0.5 million in other income in the year ending December 31, 2023 related to net license royalties.
Total Operating Expenses from Continuing Operations
- Total operating expenses from continuing operations for 2023 were $9.8 million, a decrease of $57.6 million, or 85.4%, compared to 2022, primarily attributable to lower general and administrative expenses due to the transition of the Company’s business from a commercializing pharmaceutical business to a royalty-based business.
Evaluation of Strategic Alternatives
- The Company continues to evaluate a variety of strategic alternatives that may include, but not be limited to, an acquisition, merger, other business combination, sale of assets, or other strategic transactions involving the Company. Although the Company is exploring potential strategic alternatives, there can be no assurance of a transaction, a successful outcome of these efforts, or the form or timing of any such outcome. The Company has not set a timetable for completion of this exploration process and does not intend to disclose further developments unless and until it is determined that disclosure is appropriate or necessary.
- Forums
- ASX - By Stock
- Ann: 2024 Half Year Investor Presentation
TherapeuticsMD reported their FY23 results yesterday and the...
-
- There are more pages in this discussion • 5 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add MYX (ASX) to my watchlist
|
|||||
Last
$4.94 |
Change
-0.175(3.42%) |
Mkt cap ! $421.9M |
Open | High | Low | Value | Volume |
$5.03 | $5.06 | $4.90 | $532.5K | 106.9K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
5 | 76 | $4.93 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$4.94 | 54 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
3 | 178 | 4.940 |
9 | 757 | 4.930 |
5 | 1842 | 4.920 |
2 | 470 | 4.910 |
2 | 471 | 4.900 |
Price($) | Vol. | No. |
---|---|---|
4.950 | 1071 | 4 |
4.960 | 1010 | 4 |
4.970 | 2277 | 5 |
4.980 | 3471 | 4 |
4.990 | 592 | 2 |
Last trade - 13.12pm 03/09/2024 (20 minute delay) ? |
Featured News
MYX (ASX) Chart |